{"title":"Inhibition of endothelial cell proliferation as a potential therapeutic approach in hereditary hemorrhagic telangectasia","authors":"Nicolas Ricard, Sabine Bailly","doi":"10.1038/s44161-024-00557-2","DOIUrl":null,"url":null,"abstract":"Arteriovenous malformations are the hallmark of patients with hereditary hemorrhagic telangectasia. Research now finds that this could be due to endothelial cell-cycle acceleration via CDK6. These results could suggest repurposing CDK6 inhibitors for this disorder.","PeriodicalId":74245,"journal":{"name":"Nature cardiovascular research","volume":"3 11","pages":"1267-1269"},"PeriodicalIF":9.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature cardiovascular research","FirstCategoryId":"1085","ListUrlMain":"https://www.nature.com/articles/s44161-024-00557-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Arteriovenous malformations are the hallmark of patients with hereditary hemorrhagic telangectasia. Research now finds that this could be due to endothelial cell-cycle acceleration via CDK6. These results could suggest repurposing CDK6 inhibitors for this disorder.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
